Senti Biosciences (SNTI) Free Cash Flow (2021 - 2025)
Senti Biosciences' quarterly Free Cash Flow came in at -$6.9 million in Q4 2025, up 49.13% year-on-year from -$4.6 million in Q4 2024, and up 27.22% quarter-over-quarter from -$9.4 million in Q3 2025.
Senti Biosciences has reported Free Cash Flow for 5 years, with the latest figure at -$6.9 million in Q4 2025.
- For the quarter ending Q4 2025, Free Cash Flow rose 49.13% year-over-year to -$6.9 million; the trailing twelve-month figure through Dec 2025 stood at -$43.6 million (down 5.35% YoY), and the FY2025 full-year result was -$43.6 million, down 5.35% from the prior year.
- Free Cash Flow for Q4 2025 stood at -$6.9 million, up from -$9.4 million in the prior quarter.
- The five-year high for Free Cash Flow was -$934675.0 in Q2 2021, with the low at -$33.6 million in Q3 2022.
- Average Free Cash Flow over 5 years is -$11.6 million, with a median of -$9.4 million recorded in 2025.
- Year-over-year, Free Cash Flow slumped 1862.94% in 2022 and surged 84.51% in 2023.
- Tracing SNTI's Free Cash Flow over 5 years: stood at -$4.5 million in 2021, then sank by 290.69% to -$17.5 million in 2022, then soared by 59.81% to -$7.0 million in 2023, then slumped by 91.73% to -$13.5 million in 2024, then surged by 49.13% to -$6.9 million in 2025.
- The last three Free Cash Flow figures came in at -$6.9 million (Q4 2025), -$9.4 million (Q3 2025), and -$13.1 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.67 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -12.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.49 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.29 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 848.30 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 48.67 Mn |
| 10 | Senti Biosciences Holdings | 22.25 Mn | 22.25 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -6.88 Mn |
| Dec 31, 2025 | -6.88 Mn |
| Sep 30, 2025 | -9.45 Mn |
| Sep 30, 2025 | -9.45 Mn |
| Jun 30, 2025 | -13.10 Mn |
| Jun 30, 2025 | -13.10 Mn |
| Mar 31, 2025 | -14.22 Mn |
| Mar 31, 2025 | -14.22 Mn |
| Dec 31, 2024 | -13.52 Mn |
| Dec 31, 2024 | -13.52 Mn |
| Sep 30, 2024 | -7.87 Mn |
| Sep 30, 2024 | -7.87 Mn |
| Jun 30, 2024 | -8.36 Mn |
| Jun 30, 2024 | -8.36 Mn |
| Mar 31, 2024 | -11.68 Mn |
| Mar 31, 2024 | -11.68 Mn |
| Dec 31, 2023 | -7.05 Mn |
| Dec 31, 2023 | -7.05 Mn |
| Sep 30, 2023 | -5.21 Mn |
| Sep 30, 2023 | -5.21 Mn |
| Jun 30, 2023 | -19.09 Mn |
| Jun 30, 2023 | -19.09 Mn |
| Mar 31, 2023 | -21.06 Mn |
| Mar 31, 2023 | -21.06 Mn |
| Dec 31, 2022 | -17.54 Mn |
| Dec 31, 2022 | -17.54 Mn |
| Sep 30, 2022 | -33.61 Mn |
| Sep 30, 2022 | -33.61 Mn |
| Jun 30, 2022 | -7.69 Mn |
| Jun 30, 2022 | -7.69 Mn |
| Mar 31, 2022 | -17.44 Mn |
| Mar 31, 2022 | -17.44 Mn |
| Dec 31, 2021 | -4.49 Mn |
| Dec 31, 2021 | -4.49 Mn |
| Sep 30, 2021 | -1.71 Mn |
| Sep 30, 2021 | -1.71 Mn |
| Jun 30, 2021 | -934,675.00 |
| Jun 30, 2021 | -934,675.00 |